The Medicines Company expects its cardiovascular outcomes trial for Inclisiran can be completed at one-tenth the cost of rival drug trials, without cutting corners
Category: NASDAQ:MDCO
The Medicines Company expects its cardiovascular outcomes trial for Inclisiran can be completed at one-tenth the cost of rival drug trials, without cutting corners